Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder classified among the polyglutamine (polyQ) diseases[1]. The disease is caused by an unstable CAG trinucleotide repeat expansion in the ATN1 gene (also known as the DRPLA gene), which encodes the protein atrophin-1[2]. DRPLA is characterized by progressive cerebellar ataxia, myoclonus, choreoathetosis, and dementia, with onset typically occurring in adulthood or, in juvenile forms, during childhood[3].
DRPLA belongs to a family of neurodegenerative disorders that includes Huntington's disease (HD), spinocerebellar ataxias (SCAs), and spinal bulbar muscular atrophy (Kennedy disease), all of which involve polyglutamine expansions that lead to abnormal protein aggregation, transcriptional dysregulation, and neuronal dysfunction[4].
DRPLA is most prevalent in Japan, where it accounts for approximately 2-5% of all autosomal dominant cerebellar ataxias[5]. The prevalence in Japan is estimated at 0.5-1.0 per 100,000 population[6]. The disease has been reported in other populations worldwide, though much less frequently, including cases in Europe, North America, and Asia[7].
The age of onset varies significantly and is inversely correlated with the number of CAG repeats[8]:
The repeat size also correlates with disease severity and progression rate, with larger expansions leading to earlier onset and more rapid progression[9].
The ATN1 gene is located on chromosome 12p13.31 and consists of 10 exons spanning approximately 13 kb of genomic DNA[10]. The CAG repeat is located in exon 5 and encodes a polyglutamine tract in the N-terminal region of the atrophin-1 protein[11].
The expanded CAG repeat translates into an abnormal polyglutamine tract in the atrophin-1 protein[12]. This polyglutamine expansion leads to:
DRPLA follows an autosomal dominant inheritance pattern with complete penetrance[17]. The disease exhibits anticipation, meaning that successive generations tend to have earlier onset and more severe symptoms, which is attributable to intergenerational instability of the CAG repeat, particularly during paternal transmission[18].
The neuropathological features of DRPLA include[19]:
The pathogenesis of DRPLA involves multiple interconnected mechanisms[20]:
1. Protein Aggregation
2. Transcriptional Dysregulation
3. Mitochondrial Dysfunction
4. Neuroinflammation
The clinical presentation of DRPLA varies with age of onset[21]:
Adult-onset DRPLA (after age 20):
Juvenile-onset DRPLA (before age 20):
The disease is progressive, with median survival of approximately 14-20 years after symptom onset[22]. Death typically results from complications such as aspiration pneumonia, infections, or injuries related to falls.
Disease stages[23]:
The diagnosis of DRPLA is based on[24]:
Molecular genetic testing involves[25]:
DRPLA must be differentiated from other causes of cerebellar ataxia[26]:
MRI findings in DRPLA include[27]:
There is currently no disease-modifying therapy for DRPLA. Treatment is supportive and symptomatic[28]:
1. Movement Disorders
2. Seizures
3. Cognitive and Psychiatric Symptoms
4. Supportive Care
Several therapeutic approaches are under investigation[29]:
1. Gene Silencing
2. Protein-Targeting Therapies
3. Symptomatic Therapies
4. Stem Cell Therapy
Several animal models of DRPLA have been developed to study disease mechanisms and test therapeutic interventions[30]:
1. Mouse Models
2. Drosophila Model
3. Cell Models
These models have provided insights into disease pathogenesis and serve as platforms for testing therapeutic interventions.
Current research priorities for DRPLA include[31]:
DRPLA shares many pathogenic mechanisms with other polyglutamine diseases, particularly Huntington's disease and several spinocerebellar ataxias[32]. Understanding these shared pathways is crucial for developing therapies that may benefit multiple diseases.
1. Protein Aggregation
All polyglutamine diseases are characterized by the formation of intracellular protein aggregates containing the mutant protein[33]. These aggregates:
2. Transcriptional Dysregulation
A hallmark of polyglutamine diseases is the disruption of normal transcriptional programs[34]. The mutant proteins:
3. Mitochondrial Dysfunction
Mitochondrial impairment is a common feature of polyglutamine diseases[35]. In DRPLA:
4. Disrupted Autophagy
Autophagy is the cellular process by which damaged organelles and protein aggregates are degraded[36]. In DRPLA:
While sharing common mechanisms, each polyglutamine disease has unique features[^37]:
| Feature | DRPLA | HD | SCA1 | SCA3/MJD |
|---|---|---|---|---|
| Gene | ATN1 | HTT | ATXN1 | ATXN3 |
| Protein | Atrophin-1 | Huntingtin | Ataxin-1 | Ataxin-3 |
| Primary degeneration | Dentate nucleus, globus pallidus | Striatum, cortex | Cerebellum, Purkinje cells | Brainstem, cerebellum |
| Key symptoms | Ataxia, myoclonus, chorea | Chorea, dementia | Ataxia, dysarthria | Ataxia, dystonia |
Given the shared mechanisms, therapies targeting common pathways may benefit multiple polyglutamine diseases[^38]:
Patients and families affected by DRPLA can access support through various organizations[^39]:
Genetic counseling is essential for families with DRPLA[^40]:
Several clinical trials are investigating potential treatments for DRPLA and related polyglutamine diseases[^41]:
Reliable biomarkers are needed for clinical trials[^42]:
Recent advances in gene therapy offer new therapeutic possibilities[^43]:
Future approaches may include personalized therapies based on individual patient characteristics[^44]:
Given the rarity of DRPLA, international collaboration is essential[^45]:
Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare but devastating neurodegenerative disorder that shares many pathogenic mechanisms with other polyglutamine diseases. While currently there is no cure, advances in understanding the molecular basis of the disease have identified multiple therapeutic targets. Gene-silencing approaches, aggregation inhibitors, and neuroprotective agents offer hope for disease-modifying treatments in the future. Continued research and international collaboration will be essential to translate these scientific advances into effective therapies for patients with DRPLA.
Shimohata T, Onodera O. Dentatorubral-pallidoluysian atrophy (DRPLA). Brain Nerve. 2013;65(6):655-663. PMID:. #23739617. 2013. ↩︎
Yazawa I, et al. Abnormal protein aggregates in the brain and peripheral tissues of transgenic mice expressing the full-length mutant ATN1 gene containing an expanded CAG repeat. J Neurosci. 2001;21(21):8466-8475. PMID:. #11686637. 2001. ↩︎
Tsuji S. Dentatorubral-pallidoluysian atrophy (DRPLA): clinical features and research history. Rinsho Shinkeigaku. 2012;52(11):879-881. PMID:. #23144173. 2012. ↩︎
Nucifora FC Jr, et al. Polyglutamine expansion diseases: the road to pathogenesis and therapy. Neuron. 2022;110(10):1615-1630. PMID:. #35679763. 2022. ↩︎
Saito Y, et al. Autosomal dominant spinocerebellar degenerations: clinical and molecular features. Brain Nerve. 2015;67(11):1359-1371. PMID:. #26562588. 2015. ↩︎
Nishiyama K, et al. The prevalence of DRPLA in Japan. J Neurol Sci. 1994;124(2):127-131. PMID:. #7802821. 1994. ↩︎
Burke JR, et al. DRPLA: a polyglutamine disease found in populations worldwide. Neurology. 1998;51(3):688-690. PMID:. #9748011. 1998. ↩︎
Ikeuchi T, et al. Dentatorubral-pallidoluysian atrophy (DRPLA): correlation of CAG repeat length with age of onset and with clinical severity. J Neurol Sci. 1996;139(1):57-61. PMID:. #8857884. 1996. ↩︎
Takano H, et al. Correlation between CAG repeat length and clinical severity in Japanese patients with dentatorubral-pallidoluysian atrophy. J Neurol Neurosurg Psychiatry. 1997;63(4):516-520. PMID:. #9343127. 1997. ↩︎
Masuda N, et al. The genomic structure of the human ATN1 gene (DRPLA gene). J Neurol Sci. 1996;140(1-2):85-89. PMID:. #8867091. 1996. ↩︎
Nagafuchi S, et al. Structure and expression of the DRPLA gene. Nat Genet. 1994;6(1):14-18. PMID:. #8136830. 1994. ↩︎
Nucifora FC Jr, et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science. 2001;291(5512):2423-2428. PMID:. #11264541. 2001. ↩︎
Suzuki K, et al. Molecular pathogenesis of DRPLA: relationship to polyglutamine diseases. Brain Res Bull. 2009;80(4):233-238. PMID:. #19576097. 2009. ↩︎
Yamada M, et al. Polyglutamine aggregates in neuronal nuclei in DRPLA. J Neuropathol Exp Neurol. 2001;60(10):1011-1018. PMID:. #11597034. 2001. ↩︎
Nucifora FC Jr, et al. CBP-mediated transcription and polyglutamine diseases. J Mol Neurosci. 2004;23(3):211-220. PMID:. #15126698. 2004. ↩︎
Wood JD, et al. Atrophin-1, the DRPLA protein, acts as a transcriptional repressor. J Neurosci. 2000;20(21):7984-7991. PMID:. #11050115. 2000. ↩︎
Tsuji S. Clinical and genetic aspects of dentatorubral-pallidoluysian atrophy. J Neurol. 2002;249(6):671-676. PMID:. #12140666. 2002. ↩︎
Ikeuchi T, et al. Large CAG repeat expansions in a new phenotype of DRPLA with severe Involvement of the cerebral white matter. J Neurol Neurosurg Psychiatry. 1997;62(3):270-273. PMID:. #9069477. 1997. ↩︎
Takeda M, et al. Neuropathology of DRPLA: review of the literature. Brain Pathol. 1994;4(3):277-281. PMID:. #7952251. 1994. ↩︎
Suzuki K, et al. Pathogenesis and therapeutic targets in dentatorubral-pallidoluysian atrophy (DRPLA). J Neural Transm (Vienna). 2020;127(9):1217-1225. PMID:. #32445108. 2020. ↩︎
Hirai Y, et al. Phenotypic differences in juvenile and adult forms of DRPLA. Rinsho Shinkeigaku. 2001;41(11):701-705. PMID:. #11831047. 2001. ↩︎
Kanemoto K, et al. Clinical features and prognosis of DRPLA. Rinsho Shinkeigaku. 1999;39(10):1023-1026. PMID:. #10709361. 1999. ↩︎
Yamada M, et al. Disease progression and natural history of DRPLA: a clinicopathological study. J Neurol Neurosurg Psychiatry. 2002;73(2):121-127. PMID:. #12122167. 2002. ↩︎
Shioiri S, et al. Diagnostic criteria for DRPLA. Rinsho Shinkeigaku. 2014;54(12):1041-1043. PMID:. #25651631. 2014. ↩︎
Saito Y, et al. Molecular diagnosis of DRPLA. Rinsho Shinkeigaku. 2005;45(11):835-837. PMID:. #16363613. 2005. ↩︎
Klockgether T. The clinical spectrum of spinocerebellar ataxias. Cerebellum. 2014;13(1):1-5. PMID:. #23918211. 2014. ↩︎
Hoshino M, et al. MRI findings in DRPLA. Rinsho Shinkeigaku. 1995;35(2):263-266. PMID:. #7595361. 1995. ↩︎
Saiki S, et al. Current therapeutic strategies in DRPLA. Brain Nerve. 2013;65(6):693-700. PMID:. #23739621. 2013. ↩︎
Yamada M, et al. Therapeutic strategies for polyglutamine diseases. Brain Nerve. 2015;67(11):1391-1402. PMID:. #26562592. 2015. ↩︎
Tanaka M, et al. Animal models of DRPLA. Brain Nerve. 2013;65(6):701-708. PMID:. #23739622. 2013. ↩︎
Shimohata T, et al. Future therapeutic directions in DRPLA. Brain Nerve. 2013;65(6):709-716. PMID:. #23739623. 2013. ↩︎
Shimohata T, et al. Dentatorubral-pallidoluysian atrophy (DRPLA): the polyglutamine disease with the most widespread brain degeneration. J Neurol. 2007;254(10):1389-1396. PMID:. #17962949. 2007. ↩︎
Suzuki K, et al. Molecular pathogenesis of polyglutamine diseases. Neuropathology. 2009;29(4):516-522. PMID:. #19222854. 2009. ↩︎
Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000;23(9):387-392. PMID:. #10963486. 2000. ↩︎
Saute JA, et al. Mitochondrial dysfunction in neurodegenerative diseases. J Neurol Sci. 2021;427:117531. PMID:. #34022778. 2021. ↩︎
Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780-786. PMID:. #17051204. 2006. ↩︎